Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical BB-101 for Diabetic Lower Leg and Foot Ulcers
NCT06383013Phase 2Recruiting
- Sponsor
- Blue Blood Biotech Corp.
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Prunbomodulin in diabetic foot ulcer (DFU), sponsored by Blue Blood Biotech Corp.. Started May 2024; status: recruiting.
02
Drugs
Prunbomodulin
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT06383013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383013.